U.S. FDA bans Emcure Pharma’s India plant over manufacturing issues

The U.S. Food and Drug Administration has banned drug imports from an India manufacturing unit of Emcure Pharmaceuticals Ltd over violations of standard manufacturing practices, the latest in a series of Indian firms to face such action. In an ‘import alert’ posted on its website on Monday, the FDA said it had barred imports from Emcure’s Hinjewadi manufacturing plant in the western Indian state of Maharashtra, after an inspection revealed the company was not meeting manufacturing quality standards. The company has nine manufacturing plants, including one in the United States, and exports to a number of countries including the U.S., Europe, Brazil and Japan, according to its website.
Medications/Drugs News Headlines – Yahoo! News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us